CRTE-7A2 is under clinical development by Beijing Corregene Biotechnology and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CRTE-7A2’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CRTE-7A2 overview

CRTE7A2-01 is under development for the treatment of HPV16-positive HLA-A 02:01-positive advanced solid tumors, including cervical cancer, head and neck tumors, anal cancer, and other tumors. The therapeutic candidate comprises of T-cells genetically engineered through lentivirus to express T cell receptors (TCR) targeting cells expressing human papillomavirus protein E7 (HPV16 E7). It is administered through intravenous route and is being developed based on SMART-TCR technology.

Beijing Corregene Biotechnology overview

Beijing Corregene Biotechnology (Corregene) discovers and develops gene editing products and therapies for genetic diseases. The company is engaged in research and development of anti-tumor immunotherapies for genetic diseases. It utilizes SMART-TCR technology optimization platform to develop tumor immunotherapy targeting solid tumor. Corregene provides research services including genome library screening, lentivirus-mediated stable cell line construction solution, knockout and gene cell line and gene-tagging cell line solutions. The company also offers lentiviral vector packaging services such as gene knockout, gene expression activation, overexpression and shRNA. It works in collaboration with pharmaceutical and biopharmaceutical to develop its products. Corregene is headquartered in Beijing, China.

For a complete picture of CRTE-7A2’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.